Longer Intervals, less treatment burden^1-4

• The recommended dose for Beovu^® is 6 mg

 

 

3 monthly injections         Treatment intervals may be individualized based on disease activity¹

• A disease assessment is suggested 16 weeks after treatment start¹

• In patients without disease activity, treatment  every 12 weeks should be considered¹

• If disease activity is detected, treatment every 8 weeks should be considered¹

*Disease activity assessed by visual acuity and/or anatomical parameters.¹

 

Beovu^® simplifies treatment⁵

• More patients in less time with a prefilled syringe^5*

Administration

The recommended dose is 6 mg brolucizumab (0.05 mL solution) administered by intravitreal injection every 4 weeks (monthly) for the first 3 doses.¹

Thereafter, the physician may individualize treatment intervals based on disease activity as assessed by visual acuity and/or anatomical parameters.¹

A disease activity assessment is suggested 16 weeks (4 months) after treatment start. In patients without disease activity, treatment every 12 weeks (3 months) should be considered. In patients with disease activity, treatment every 8 weeks (2 months) should be considered.¹

The physician may further individualize treatment intervals based on disease activity.¹

If visual and anatomical outcomes indicate that the patient is not benefiting from continued treatment, Beovu^® should be discontinued.¹

 

^{*Reference supports the concept of a prefilled syringe treating more patients in less time, but is not specific to Beovu®.}

REFERENCE

1. Summary of Product Characteristics. Novartis; 2020.

2. Data on file. RTH258-C002 Clinical Study Report. Novartis; 2018.

3. Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725-731.e1. doi:10.1016/j.ajo.2015.06.023.

4. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127-140.

5. Souied E, Nghiem-Buffet S, Leteneux C, et al. Ranibizumab prefilled syringes: benefits of reduced syringe preparation times and less complex preparation procedures. Eur J Ophthalmol. 2015;25(6):529-534.

 

Beovu^® SmPC